InMed Pharmaceuticals, Inc. (INM)
1.43
-0.03
(-2.05%)
USD |
NASDAQ |
Aug 24, 16:00
InMed Pharmaceuticals Debt to Equity Ratio : 0.061 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.061 |
| December 31, 2025 | 0.0555 |
| September 30, 2025 | 0.0552 |
| June 30, 2025 | 0.0552 |
| March 31, 2025 | 0.1209 |
| December 31, 2024 | 0.1535 |
| September 30, 2024 | 0.126 |
| June 30, 2024 | 0.1046 |
| March 31, 2024 | 0.0964 |
| December 31, 2023 | 0.0914 |
| September 30, 2023 | 0.0306 |
| June 30, 2023 | 0.0324 |
| March 31, 2023 | 0.0401 |
| December 31, 2022 | 0.0417 |
| September 30, 2022 | 0.0635 |
| June 30, 2022 | 0.0874 |
| March 31, 2022 | 0.0848 |
| December 31, 2021 | 0.0741 |
| September 30, 2021 | 0.0171 |
| June 30, 2021 | 0.0366 |
| March 31, 2021 | 0.0283 |
| December 31, 2020 | 0.0415 |
| September 30, 2020 | 0.073 |
| June 30, 2020 | 0.0539 |
| March 31, 2020 | 0.0474 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.0398 |
| September 30, 2019 | 0.0336 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| NervGen Pharma Corp. | 0.00 |
| Milestone Pharmaceuticals, Inc. | 7.785 |
| Clearmind Medicine, Inc. | 0.0075 |
| Lexaria Bioscience Corp. | 0.0183 |
| Target Group, Inc. (Canada) | -1.291 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 9.134M |
| Total Liabilities (Quarterly) | 2.242M |
| Shareholders Equity (Quarterly) | 6.892M |
| Current Ratio | 3.115 |
| Net Debt Paydown Yield | 4.95% |